Journal
VACCINE
Volume 27, Issue 16, Pages 2251-2257Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2009.02.024
Keywords
Influenza vaccine adjuvant; Computer simulation; Older adults
Categories
Funding
- National Institute General Medical Sciences Models of Infectious Agent Study (MIDAS) [U01-GM070749]
Ask authors/readers for more resources
Immunosenescence decreases influenza vaccine efficacy in older adults (age 65 and over). Strategies such as vaccine adjuvants are being developed to overcome immunosenescence. Our computer simulation model represented the decision to give an older adult either standard influenza vaccine or adjuvanted influenza vaccine and found the adjuvanted vaccine to be dominant in many scenarios, resulting in lowered cost and greater effectiveness. An adjuvanted vaccine that is 100% effective in overcoming immunosenescence remained dominant until its cost exceeded the standard vaccine cost by $65. In a single influenza season, the adjuvant would prevent 496,533 influenza cases, 171,981 hospitalizations, and 70,429 deaths. (C) 2009 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available